Focusing on Improving Patient Outcomes in Infectious Diseases
Latest News
News / 26 Mar 2021
Summit Therapeutics Announces Rights Offering
News / 17 Mar 2021
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2020
News / 23 Nov 2020
Summit Therapeutics Appoints Dr. Mahkam (“Maky”) Zanganeh as Chief Operating Officer
We are building a very different antibiotics company that focuses on bringing innovation to antibiotic development. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers.
Chief Executive Officer
Ridinilazole for CDI
Find out more about our precision antibiotic ridinilazole for the treatment of CDI
Shareholder Meetings
On 19 August 2020, a Court Meeting followed by a General Meeting will be held to approve the Company's redomicile to the US
AIM Delisting FAQs
A set of frequently asked questions about the AIM delisting is available for download